A phase 1/2 study of carfilzomib in Japanese patients with relapsed and/or refractory multiple myeloma

We conducted a phase 1/2 study of single‐agent carfilzomib in Japanese patients with relapsed/refractory multiple myeloma. Safety, pharmacokinetics and pharmacodynamics of carfilzomib were examined in phase 1. The primary endpoint in phase 2 was the overall response rate (ORR). Carfilzomib was admin...

Descripción completa

Detalles Bibliográficos
Autores principales: Watanabe, Takashi, Tobinai, Kensei, Matsumoto, Morio, Suzuki, Kenshi, Sunami, Kazutaka, Ishida, Tadao, Ando, Kiyoshi, Chou, Takaaki, Ozaki, Shuji, Taniwaki, Masafumi, Uike, Naokuni, Shibayama, Hirohiko, Hatake, Kiyohiko, Izutsu, Koji, Ishikawa, Takayuki, Shumiya, Yoshihisa, Kashihara, Tomohisa, Iida, Shinsuke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Haematological Malignancy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4785611/
https://www.ncbi.nlm.nih.gov/pubmed/26732066
http://dx.doi.org/10.1111/bjh.13900

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4785611/
https://www.ncbi.nlm.nih.gov/pubmed/26732066
http://dx.doi.org/10.1111/bjh.13900

Ejemplares similares